Main > > >CRITICAL/INTENSIVE CARE MEDICINE.*
Acute Coronary Syndrome. Treat.: Tiro-fiban Hydrochloride.
Cleared in USA & in >60 Countries WW.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.22.
Air Embolism. PREVENTION.
EU Approval Date : 2016. 12.15.
USA Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.07.
Arrhytmia. VF (Ventricular Fibrillation)
& VT (Ventricular Tachycardia) Treat.:
Amiodarone.HCl Inj. Generic.
Shelf Life: 2-24 hours
(*) Company: Fresenius Kabi USA
UpDate: 2019. 02.25.
Arrhytmia. VF (Ventricular Fibrillation)
& VT (Ventricular Tachycardia) Treat.:
Amiodarone.HCl PreMixed Inj.
Shelf Life: 24 months
USA Approval Date: ?
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.25.
Atrial Fibrillation Conversion to Synus
Rhythm>Vernakalant.HCl Inj.
Non-Surgery Patients with AFi < 7 days
Post Cardiac Surgery Patients with AFi<
3 days.
CA Approval Date: 2017. 03.14.
CA Launch Date: 2018. 10.24.
EU Approval Date: 2010. 09.
(*) Companies; Patents; TradeMark &
Web-Sites Available on Request.
UpDate: 2021. 02.06.
Atrial Fibrillation or Atrial Flutter in PeriOperative, PostOperative, or other Emergent situations.
Ventricular Rate Rapid Control: Esmolol HCl in Water for Injection. GENERIC.
USA Launch Date: 2018. 03.01.
(*) Company: WG Critical Care.
www.wgcriticalcare.com
UpDate: 2018. 03.02.
Automated Glycemic Control. Continuous Real-time Diagnostics.
EU CE Mark Date: 2020. 10.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.08.
Blood Coagulation Point Of Care (POC)
Status Hemostasis DIAG. System.
Technology uses UltraSound ..
EU Approval Date : 2019. 09.10>
>Liver & Trauma Surgeries
USA Approval Date: 2019. 03.13>
>CardioVascular (CV) & Orthopedic Surge
ries.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 10.17.
Blood Loss Detection Technology.
Emergency Medicine.
USA Clearance Date: 2018. 07.24.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.20.
Cardio.>Arrhytmia. Atrial Fibrillation Treat.: Vernakalant.HCl.
CA Approval Date: 2017. 03.14.
CA Launch Date : 2018. 10.24.
EU Approval Date: 2010. 09.
(*) Companies; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 03.21.
Cuff Pressure Regulator.
DIST.: AU; BR; IL & USA
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.12.
Forehead Sensor>Single-Patient-Use.
Description:
This single-patient-use sensor allows clinicians to monitor patients using Measure-through Motion and Low Perfusion™ pulse oximetry from an alternative monitoring site, the forehead, rather than a finger.
Single-Patient-Use Forehead Sensor
Forehead sensors may provide oxygen saturation measurements that are less susceptible to peripheral perfusion changes, and were shown in a 2004 study to have faster detection of desaturation and resaturation, as compared to digit sensors.1 Forehead sensors can also be easily accessed during surgery and resuscitation and on patients with finger deformities or whose fingers are not accessible. As a single-patient-use sensor, avoids the management complexities (cleaning, storage, and inter-department transport) that accompany reusable sensors.
includes measurement of oxygen saturation (SpO2), pulse rate (PR), perfusion index (PI), and PVI®, a measure of the dynamic changes in PI that occur during the respiratory cycle.
addresses the challenges of low perfusion and motion artifact that limit conventional pulse oximetry by harnessing the power of adaptive filters to reduce measurement inaccuracy.
helps clinicians monitor more than 100 million patients a year2 and is used by 8 of the top 10 hospitals listed in the 2016-17 U.S. News and World Report Best Hospitals Honor Roll.3.
USA Approval Date: 2016. 12.19.
(*) Company; TradeMark & Web-Site
Available on Request.
UpDate: 2018. 01.07.
HyperKalemia. TREAT.: Na Zr CycloSili-
cate.
- Cardiovascular:
risk of hyperkalaemia increases for
patients who take common medications
for heart failure (HF), such as renin-
angiotensin-aldosterone system (RAAS)
inhibitors, which can increase
potassium in the blood.
- Metabolic.
- Renal (Nephrology):
risk of hyperkalaemia increases
significantly for patients with
chronic kidney disease (CKD)
EU Approval Date: 2018. 03.22.
USA Approval Date: 2018. 05.18.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 05.22.
HyperTension. Short Term Treat.: Nicar-
dipine.HCl Premixed Inj.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.19.
HypoKalemia. TREAT.: KCl Oral Solution.
Generics.
USA Approval & Launch Date: 2018. 07.23.
(*) Company: Amneal Pharma.
UpDate: 2018. 07.24.
HypoKalemia. TREAT.: KCl Powder for Oral Solution.
USA Launch Date: 2017. 11.28.
(*) Company; TradeMark & Web-Site Available on Request.
UpDate: 2017. 11.29.
HypoTension. TREAT.: Angiotensin II Injection for IntraVenous Infusion
Increases Blood Pressure in Adults with Septic or other Distributive Shock.
HepatoRenal Syndrome (HRS) is Progressive Renal Failure associated with Liver Cirrhosis or Fulminant Liver Failure.
EU Approval Date: 2019. 08.
USA Approval Date: 2017. 12.21.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.02.
HypoTension. TREAT.: Ephedrine Sulfate Injection USP 50 mg/
mL. Brand.
USA Approval Date: 2016. 04.29.
USA Launch Date: 2016. 08.12.
(*) Company; TradeMark & Web-Site Available on Request.
UpDate: 2018. 01.07.
HypoTension. TREAT.: Ephedrine Sulfate Injection USP 50 mg/
mL. Generic.
USA Approval Date: 2017. 03.02.
(*) Company & Web-Site Available on Request.
UpDate: 2018. 01.07.
HypoTension. TREAT.: Vasopressin Injection.
Indication>Vasodilatory Shock>>e.g., Post-Cardiotomy or Sepsis.
USA Approval Date: 2014. 04.17.
(*) Company; Patent; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.07.
Lung Failure>Augmented Respiratory Tech-
nology (ART).
Patent>USA>Filed: 2020. 12.03
Tested on COVID-19 at Top World-Ranked
Hospital.
(*) Company & Web-Site Available on
Request.
UpDate: 2021. 03.21.
Lung Failure>ECMO (ExtraCorporeal Mem- brane Oxygenation).
USA Approval : 2020. 10.26.
USA 1st Patients Treat.: 2020. 12.21.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.01.
Malignant Hyperthermia. TREAT.: Dantrolene Na for Injectable
Suspension.
USA Approval Date: 2014. 08.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 01.07.
Neuro.>Stroke. Treat.: Cooling.
USA Approval Date: 2018. 05.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.07.
Patient Body Temperature Continuous Non-Invasive Monitoring. Hospitals.
Patch placed on the Underarm Skin of Patients to Continuously Measure Axillary Body Temperature for up to 72 Hours.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 07.22.
Respiratory Distress>Dyspnea; Hypercap- nia; Hypoxemia. Treat.: High Velocity Humidified Warm Oxygen Nasal Insuffla-tion.
Mask-Free Non Invasive Ventilation (NIV) for Spontaneously Breathing.
While being Treated Patients can Talk, Eat, Drink & take Oral Medication.
Release 2nd Generation Date: 2019. 02.13
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.26.
Supraventricular Tachycardia (ST). Treat
.: Esmolol.HCl for Inj.
Launched in BE & FR
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.05.
Supraventricular Tachycardia (ST). Treat
.: Landiolol.HCl for Inj.
AT & DE Launch: 2017. 06.19.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.06.
Vital Signs Continuous Disposable Sensor.
Disposable peel-and-stick health sensor, which continuously monitors eight different vitals (ECG, heart rate, heart rate variability, respiratory rate, skin temperature, posture, and steps, as well as automatic fall detection) in real-time. It s designed for inpatient and outpatient hospital use. Via Bluetooth, the sensors send the data to either a connected app or hub, then onwards to a cloud-based server where it can be accessed by the user s care providers.
“Since the product is fully disposable, how many days you can have it is an important factor. This is not a rechargeable device or changing the battery or anything like that,”
USA>FDA>Clearance, Lengthening the Life of its Device from 4 days to 5 on 2017. 12.07.
(*) Company; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2017. 12.08.
>CRITICAL/INTENSIVE CARE MEDICINE.*'s products
This section has no products